Friday, December 18, 2020

Every Patient Treated With CRISPR Gene Therapy for Blood Diseases Continues to Thrive, More Than a Year On

18 months into the first serious clinical trials of CRISPR gene therapy for sickle cell disease and beta-thalassemia—and all patients are free from symptoms and have not needed blood transfusions. Sickle cell disease (SCD) can cause a variety of health problems including episodes of severe pain, called vaso-occlusive crises, as well as organ damage and […]

The post Every Patient Treated With CRISPR Gene Therapy for Blood Diseases Continues to Thrive, More Than a Year On appeared first on Good News Network.



from Good News Network https://ift.tt/3h7qL2H

No comments:

Post a Comment

Home